A roughly 5.5% single-session drop in Lineage Cell Therapeutics, Inc (NYSE American:LCTX) fits a pattern familiar to small-cap biotech investors: sharp moves with no obvious explanation. Underneath that daily swing sits a more durable story, a clinical-stage developer of allogeneic cell therapies anchored by …
LENZ Therapeutics, Inc (NASDAQ:LENZ) has spent 2026 transitioning from a clinical-stage hopeful into a commercial eye-care company, and its shares have been volatile as investors gauge the early trajectory of its first approved product.
After a difficult fiscal year, LifeVantage Corporation (NASDAQ: LFVN) is drawing renewed interest from small-cap investors trying to gauge whether a turnaround is taking shape. The nutrition and personal-care company's shares recently ticked higher to around $6.51, giving it a marketCapitalizationnear $82 million, and …
● LianBio was built to in-license and develop therapies for the Greater China and broader Asian markets, assembling a portfolio that included the cardiovascular drug mavacamten and other candidates licensed from Western partners.
A near-flatTrading sessioncan hide a surprisingly eventful corporate story. Lunai Bioworks Inc. (NASDAQ:LNAI) barely moved in its most recent session, yet the company behind the ticker has been anything but static: a fresh name, a reverse stock split, a blood-brain-barrierAcquisitionand new research collaborations have …
ChromoCure, Inc (OTC:KKUR) sits at the far, speculative edge of the health-technology market: a nano-cap over-the-counter security quoted at a small fraction of a penny. There is no confirmed recent catalyst, no verifiable stream of company news, and very little public financial disclosure to …
After a turbulent stretch, Keros Therapeutics (NASDAQ: KROS) has become a study in strategic focus. The clinical-stage biopharmaceutical company spent much of 2025 reshaping its pipeline and leadership, and it enters the autumn of 2026 as a leaner developer concentrated on a single lead …
● The pullback is consistent with the everydayVolatilityof a small clinical-stage biotech rather than any confirmed setback.
● Founded in 1993 and headquartered in San Francisco, the company adopted the Kyntra Bio name in January 2026 following what management described as a transformational 2025 that included the sale of its FibroGen China business,Debtrepayment and rebranding.
Few life-sciences tools companies are mid-transformation quite as dramatically as Standard BioTools. The proteomics and genomics instrument maker has spent 2026 negotiating its way toward a sweeping all-stock combination, and its shares, trading around $0.73 with a marketCapitalizationnear $285 million, recently ticked higher by …